SOURCE: Jesup & Lamont

February 22, 2007 14:27 ET

Jesup & Lamont Initiates Coverage of Generex Biotechnology With "Buy" Rating and Price Target of $3.25

NEW YORK -- (MARKET WIRE) -- February 22, 2007 -- Jesup & Lamont, a New York-based full-service brokerage and investment banking firm, announced today that it has initiated coverage of Generex Biotechnology (NASDAQ: GNBT) with a "Buy" rating and 12-18 month price target of $3.25 per share.

Senior Healthcare Analyst Robert M. Wasserman noted that, "Generex has a deep pipeline, an active industry education program (particularly in the worldwide diabetes market), growing product sales, and plenty of financial resources to provide investors with value-producing progress in the near future."

Contact Information

  • For further information, contact:
    Robert Wasserman
    Jesup & Lamont
    (561) 208-1994